112 related articles for article (PubMed ID: 35081053)
21. Prognostic Importance of Comorbidity and the Association Between Comorbidity and p16 in Oropharyngeal Squamous Cell Carcinoma.
Skillington SA; Kallogjeri D; Lewis JS; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):568-75. PubMed ID: 27077485
[TBL] [Abstract][Full Text] [Related]
22. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
[TBL] [Abstract][Full Text] [Related]
23. Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials.
Lassen P; Overgaard J; Eriksen JG
Radiother Oncol; 2013 Sep; 108(3):489-94. PubMed ID: 24060179
[TBL] [Abstract][Full Text] [Related]
24. Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer.
Burr AR; Harari PM; Ko HC; Bruce JY; Kimple RJ; Witek ME
Oral Oncol; 2019 May; 92():52-56. PubMed ID: 31010623
[TBL] [Abstract][Full Text] [Related]
25. Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma.
Huber GF; Albinger-Hegyi A; Soltermann A; Roessle M; Graf N; Haerle SK; Holzmann D; Moch H; Hegyi I
Cancer; 2011 Oct; 117(20):4659-70. PubMed ID: 21448927
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and staging value of tumor deposits in patients with rectal cancer after neoadjuvant chemoradiotherapy.
Xu T; Yu Z; Zhang Q; Liu B; Li Y; Wang F
Transl Cancer Res; 2021 Dec; 10(12):5028-5039. PubMed ID: 35116355
[TBL] [Abstract][Full Text] [Related]
27. Oropharyngeal cancer: First relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric study.
Culié D; Lisan Q; Leroy C; Modesto A; Schiappa R; Chamorey E; Dassonville O; Poissonnet G; Guelfucci B; Bizeau A; Vergez S; Dupret-Bories A; Garrel R; Fakhry N; Santini L; Lallemant B; Chambon G; Sudaka A; Peyrade F; Saada-Bouzid E; Benezery K; Jourdan-Soulier F; Chapel F; Ramay AS; Roger P; Galissier T; Coste V; Lakdar AB; Temam S; Gorphe P; Guerlain J; Bozec A; Mirghani H
Eur J Cancer; 2021 Jan; 143():168-177. PubMed ID: 33333482
[TBL] [Abstract][Full Text] [Related]
28. Combination of p16 levels and pre-radiotherapy factors predicts outcome in patients treated for oropharyngeal carcinoma.
Bar-Ad V; Wang ZX; Leiby B; Tuluc M
J BUON; 2013; 18(4):982-8. PubMed ID: 24344027
[TBL] [Abstract][Full Text] [Related]
29. A Systematic Review and Meta-Analysis of Prognostic Biomarkers in Anal Squamous Cell Carcinoma Treated With Primary Chemoradiotherapy.
Parwaiz I; MacCabe TA; Thomas MG; Messenger DE
Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):e1-e13. PubMed ID: 31301958
[TBL] [Abstract][Full Text] [Related]
30. FDG-PET/CT scan assessment of response 12 weeks post radical radiotherapy in oropharynx head and neck cancer: The impact of p16 status.
Urban R; Godoy T; Olson R; Wu J; Berthelet E; Tran E; DeVries K; Wilson D; Hamilton S
Radiother Oncol; 2020 Jul; 148():14-20. PubMed ID: 32294581
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
32. Negative Prognostic Impact of Tumor Deposits in Rectal Cancer: A National Study Cohort.
Agger E; Jörgren F; Jöud A; Lydrup ML; Buchwald P
Ann Surg; 2023 Sep; 278(3):e526-e533. PubMed ID: 36538637
[TBL] [Abstract][Full Text] [Related]
33. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
34. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
[TBL] [Abstract][Full Text] [Related]
35. Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma.
Zenga J; Wilson M; Adkins DR; Gay HA; Haughey BH; Kallogjeri D; Michel LS; Paniello RC; Rich JT; Thorstad WL; Nussenbaum B
JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1118-27. PubMed ID: 25902372
[TBL] [Abstract][Full Text] [Related]
36. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
37. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
[TBL] [Abstract][Full Text] [Related]
38. Impact of p16 expression in oropharyngeal cancer in the postoperative setting: the necessity of re-evaluating traditional risk stratification.
Lee J; Chang JS; Kwon HJ; Kim SH; Shin SJ; Keum KC
Jpn J Clin Oncol; 2016 Oct; 46(10):911-918. PubMed ID: 27474125
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
40. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
